This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In the current issue of Neurology, Saida et al.1 report the results of a randomized, controlled study of two doses of interferon beta-1b in Japanese patients with multiple sclerosis (MS). The study demonstrated superiority of the higher dose, consistent with the results seen in the North American study.2 Unlike the North American study, the study was not placebo-controlled. However, it was conducted between 1995 and 1999, well after the positive results of the North American interferon beta-1b study were announced, and the investigators believed that it would be unethical to conduct a placebo-controlled study. The efficacy of interferon beta in relapsing remitting patients with MS is well established. What does the current study add? This is the first study of interferon beta treatment from Asia. Ethnic differences are often associated with genetic variations; pharmacogenetic studies addressing responsiveness to interferon beta therapy are in their infancy, but …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
